Dr. Iyer on Treatment of Patients With Lung NETs

Renuka Iyer, MD
Published: Tuesday, Dec 15, 2015



Renuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors (NETs).

From a disciplinary perspective, gastointestinal (GI) NETs differ from lung NETs, Iyer explains, in that the first condition is treated by medical oncologists versus thoracic oncologists.

Guidelines for treatment of lung NETs are thought to be controversial, as it is recommended to treat lung NETs as small cell lung cancer (SCLC). However, the biology of lung NETs closely resemble GI NETS, she adds. In discussing a case study where a patient with a lung NET was treated as SCLC, Iyer explains that their survival outcome was similar to a patient with a GI NETs, which was approximately 4 to 5 years.

SELECTED
LANGUAGE


Renuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors (NETs).

From a disciplinary perspective, gastointestinal (GI) NETs differ from lung NETs, Iyer explains, in that the first condition is treated by medical oncologists versus thoracic oncologists.

Guidelines for treatment of lung NETs are thought to be controversial, as it is recommended to treat lung NETs as small cell lung cancer (SCLC). However, the biology of lung NETs closely resemble GI NETS, she adds. In discussing a case study where a patient with a lung NET was treated as SCLC, Iyer explains that their survival outcome was similar to a patient with a GI NETs, which was approximately 4 to 5 years.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x